Therapix Signs Exclusive License Agreement with Yissum for Nasal Drug Delivery Technology Agreement Paves the Way for Development and Marketing of New Cannabinoid-based Treatment Offerings for Mild Cognitive Impairment...

Therapix Biosciences Provides Portfolio Update TEL AVIV, Israel, January 11, 2017 /PRNewswire/ — Therapix Biosciences (OTCQB: THXBY) (TASE: THXBY.TA), a clinical-stage pharma company specializing in the development of cannabinoid-based...